Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients. Since a common mutation that replaces Gly(2019) with a serine residue enhances kinase catalytic activity, small-molecule LRRK2 inhibitors might have utility in treating Parkinson...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Dzamko, Nicolas, Deak, Maria, Hentati, Faycal, Reith, Alastair D., Prescott, Alan R., Alessi, Dario R., Nichols, R. Jeremy
Format: Artigo
Jezik:Inglês
Izdano: Portland Press Ltd. 2010
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3631100/
https://ncbi.nlm.nih.gov/pubmed/20659021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20100784
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items